GLP1R and pancreatic neoplasm: Among secondary outcomes, GLP-1 RA Users showed a higher risk of acute pancreatitis (HR 1.058, 95% CI 1.015–1.103), while no statistically significant differences were observed for chronic pancreatitis (HR 0.973, 95% CI 0.906–1.045) or pancreatic cancer (HR 1.031, 95% CI 0.952–1.116) (Table 2).